Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Acceleron Pharma Inc patents


Recent patent applications related to Acceleron Pharma Inc. Acceleron Pharma Inc is listed as an Agent/Assignee. Note: Acceleron Pharma Inc may have other listings under different names/spellings. We're not affiliated with Acceleron Pharma Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Acceleron Pharma Inc-related inventors


Treatment of beta-thalassemia using actrii ligand traps

Provided herein are methods of treating beta-thalassemia by subcutaneous administration of about 0.8 mg/kg of an actrii signaling inhibitor. Also provided herein are methods of adjusting the dose of the actrii signaling inhibitor administered to the subject.. ... Acceleron Pharma Inc

Method for decreasing the body fat content in a subject by administering an actriib protein

In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.. . ... Acceleron Pharma Inc

Compositions and methods for treating pulmonary hypertension

In some aspects, the disclosure relates to gdf/bmp antagonists and methods of using gdf/bmp antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (ph), particularly treating, preventing or reducing the progression rate and/or severity of one or more ph-associated complications. The disclosure also provides methods of using a gdf/bmp antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. ... Acceleron Pharma Inc

Methods and compositions for treating myelofibrosis

In part, the present disclosure relates methods for treating, preventing, or reducing the progression rate and/or severity of myelofibrosis or one or more complications of myelofibrosis (extramedullary hematopoiesis, splenomegaly, anemia, and fibrosis). In certain aspects, the disclosure provides actriib antagonists for use in treating, preventing, or reducing the progression rate and/or severity of one or more complications associated with janus kinase inhibitor therapy in a patient (e.g., anemia).. ... Acceleron Pharma Inc

Methods for treating refractory anemia with ringed sideroblasts

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.. . ... Acceleron Pharma Inc

Antagonists of actriib and uses for increasing red blood cell levels

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.. . ... Acceleron Pharma Inc

Activin-actrii antagonists and uses for treating anemia

Provided herein are methods for the treatment in a subject of anemia, anemia requiring rbc transfusion, low or intermediate-1-risk myelodysplastic syndromes (mds), and/or non-proliferative chronic myelomonocytic leukemia (cmml) in any mammals wherein the methods comprise administration of activin-actrii signaling inhibitors to a subject in need of the treatment.. . ... Acceleron Pharma Inc

Alk1 receptor and ligand antagonists and uses thereof

In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase i (alk1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for alk1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.. ... Acceleron Pharma Inc

Methods and compositions for treating ineffective erythropoiesis

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.. . ... Acceleron Pharma Inc

Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy

In certain aspects, the present invention provides compositions and methods for inducing utrophin expression in muscle with an actriib protein as therapy for muscular dystrophy. The present invention also provides methods of screening compounds that modulate activity of an actriib protein and/or an actriib ligand.. ... Acceleron Pharma Inc

Alk7 antagonists and uses thereof

In certain aspects, the disclosure provides alk7 antagonists. In certain aspects, these alk7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. ... Acceleron Pharma Inc

Methods for treating eye disorders

Disclosed herein are compositions and methods for increasing visual acuity in patients in need thereof and for treating vascular disorders of the eye.. . ... Acceleron Pharma Inc

Bmprii polypeptides and uses thereof

In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of bone morphogenetic protein receptor type ii (bmprii) polypeptide binds to ligands including bmp10, bmp15, activin b and bmp9 and may be used to treat fibrotic and angiogenic disorders.. . ... Acceleron Pharma Inc

Methods for increasing red blood cell levels and treating ineffective erythropoiesis

In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in a subject in need thereof. Subjects in need include, for example, subjects having anemia and/or ineffective erythropoiesis as a result of having reduced gata-1, heat shock factor and/or nfe2 levels as compared to the levels in a reference population.. ... Acceleron Pharma Inc

08/24/17 / #20170240639

Actrii antagonists for use in increasing immune activity

Disclosed herein are actrii antagonists and methods for increasing immune responses and/or activity in patients in need thereof including, for example, cancer patients. In some embodiments, the disclosure relates to methods for treating cancer and/or tumors in a patient comprising administration of an actrii antagonists and a pd1-pdl1 antagonist.. ... Acceleron Pharma Inc

07/20/17 / #20170204382

Isolated gdf trap polypeptide

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.. . ... Acceleron Pharma Inc

07/06/17 / #20170190784

Activin-actriia antagonists and uses for treating multiple myeloma

In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.. . ... Acceleron Pharma Inc

05/18/17 / #20170137791

Methods and compositions for treating ineffective erythropoiesis

In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.. . ... Acceleron Pharma Inc

05/18/17 / #20170137503

Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof

In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase i (alk1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. In certain aspects, the disclosure demonstrates that antagonists of bmp9 and/or bmp10, ligands for alk1, may also be used to inhibit angiogenesis in vivo.. ... Acceleron Pharma Inc

03/02/17 / #20170058016

Variants derived from actriib and uses therefor

In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an actriib protein and/or an actriib ligand. ... Acceleron Pharma Inc

02/09/17 / #20170037100

Methods for treating myeloproliferative disorders

In part, the present disclosure relates methods for treating, preventing, or reducing the severity of a myeloproliferative disorder (e.g., polycythemia vera, essential thrombocythemia, and myelofibrosis) or one or more complications of a myeloproliferative disorder. The present disclosure further relates methods for treating, preventing, or reducing the severity of a janus kinase-associated disorder or one or more complications of a janus kinase-associated disorder. ... Acceleron Pharma Inc

01/19/17 / #20170015751

Actriia binding agents and uses thereof

The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to actriia and uses for same.. . ... Acceleron Pharma Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Acceleron Pharma Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Acceleron Pharma Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###